Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is transforming from a traditional Chinese medicine enterprise into a comprehensive health group by integrating medicine, health food, and medical services, leveraging its long history and technological innovation [1][7]. Group 1: Company Overview - Guangdong Wannianqing has over 130 years of history and has recently acquired upstream enterprises to enter the health food sector, creating a one-stop health management platform [1]. - The company has been recognized as a "Chinese Time-honored Brand" by the Ministry of Commerce in 2024, highlighting its craftsmanship and quality in the traditional Chinese medicine market [2]. - Currently, the company holds 101 drug approvals, including 32 original products and 38 products listed in the national medical insurance directory [2]. Group 2: Innovation and Technology - The company is focusing on modernizing traditional Chinese medicine through technological innovation, employing techniques such as vacuum low-temperature technology and ultra-fine pulverization to enhance production efficiency and product quality [4][5]. - A dual-driven model of "independent research and cooperative research" is being implemented to foster innovation in drug development, particularly in areas like gallbladder, diabetes, and cardiovascular diseases [5][6]. Group 3: Market Expansion and Ecosystem - Guangdong Wannianqing is building a comprehensive health ecosystem that integrates pharmaceutical manufacturing, healthcare, and health consumer products, aiming for a closed-loop system from cultivation to sales [7][8]. - The company has plans to develop health food products based on the "medicinal food homology" concept and is focusing on expanding its overseas market presence, particularly in Southeast Asia [8].

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is transforming from a traditional Chinese medicine enterprise into a comprehensive health group by integrating medicine, health food, and medical services, leveraging its long history and technological innovation [1][4]. Group 1: Company Overview - Guangdong Wannianqing has over 130 years of history and has been recognized as a "Chinese Time-Honored Brand" by the Ministry of Commerce in 2024, marking its craftsmanship and quality in the traditional Chinese medicine market [1][2]. - The company currently holds 101 drug approvals, 32 original innovative products, and 38 products listed in the national medical insurance catalog, with key products including Shenshuijian Sugar-Lowering Tablets and Yixin Pills [1][2]. Group 2: Innovation and Technology - The company is implementing a "traditional craftsmanship + intelligent manufacturing" development model, focusing on modernizing production while preserving traditional techniques [3][4]. - Innovative technologies such as vacuum low-temperature belt technology and ultra-fine pulverization are being utilized to enhance the efficiency and quality of traditional Chinese medicine production [3][4]. Group 3: Research and Development - Guangdong Wannianqing employs a "dual-wheel drive" model for R&D, focusing on both independent and collaborative research, particularly in areas like gallbladder and cardiovascular drugs [4]. - The company collaborates with Shantou University to promote the rapid transformation of research results into practical applications, enhancing its core competitiveness [4]. Group 4: Market Expansion and Ecosystem - The company is building a comprehensive health ecosystem that integrates pharmaceutical manufacturing, healthcare, and health consumer products, aiming to transition into a comprehensive health group [5][6]. - Recent acquisitions, such as the 85% stake in Guangdong Tongren Pharmaceutical Co., Ltd., allow the company to better control the quality of medicinal materials and streamline the production process [5][6]. - The company is also expanding its health food business, focusing on high-end products like bird's nest and health teas, and plans to establish a "China Bird's Nest Port" in Shantou to enhance supply chain management [6].

调研中，李强主持召开座谈会。听取有关企业和投资、研发、医疗机构负责人发言后，李强指出，生物 医药产业既是战略性新兴产业，也事关人民健康福祉。要加强原始创新和关键核心技术攻关，发挥政府 和市场两方面作用，充分调动各类资源，凝聚创新合力，尽快取得更大突破。要注重运用人工智能全面 赋能产业发展，提高药物研发、临床试验、诊断治疗、生产流通等环节智能化水平。要强化产品研发、 审评审批、管理使用等政策衔接和协同配合，优化药品集采和谈判议价机制，加大高水平创新药应用指 导力度。李强强调，要依靠创新促进中医药振兴发展，充分运用现代科学的理论、技术、材料等，深化 中医药基础理论、诊疗规律、作用机理的研究阐释，丰富治疗方法，推进中医药现代化、产业化。 原标题：李强在北京调研生物医药产业发展时强调加大高质量科技供给和政策支持着力推动生物医药产 业提质升级 新华社北京8月20日电中共中央政治局常委、国务院总理李强8月20日在北京调研生物医药产业发展情 况。他强调，要深入贯彻习近平总书记关于生物医药产业发展的重要指示精神，加大高质量科技供给和 政策支持，充分发挥企业创新主体作用，着力推动生物医药产业提质升级，研发生产更多优质高效的好 ...

Core Insights - The Chinese government emphasizes the importance of advancing the biopharmaceutical industry to enhance public health and well-being, focusing on high-quality drug development and innovation [1][2] Group 1: Government Initiatives - The government aims to increase support for high-quality technological supply and policy backing to promote the biopharmaceutical industry's upgrade and innovation [1] - There is a call for collaboration in research focusing on new targets, compounds, and mechanisms to produce significant original results and cultivate high-end talent in life sciences [1] - The government recognizes the vast market potential for innovative drugs and encourages timely identification of high clinical value projects, enhancing tracking services for these innovations [1] Group 2: Industry Development - The biopharmaceutical sector is identified as a strategic emerging industry that directly impacts public health, necessitating original innovation and tackling key core technologies [2] - The integration of artificial intelligence is highlighted as a means to enhance various stages of drug development, clinical trials, diagnostics, and production [2] - There is a focus on optimizing the operational models of research platforms to facilitate the application of scientific and technological achievements in the biopharmaceutical field [2]

Core Insights - The Chinese government emphasizes the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry, aiming for the development of more effective new drugs to improve public health [2][3] Group 1: Government Initiatives - The government aims to accelerate the biopharmaceutical sector by increasing technological innovation and focusing on new targets, compounds, and mechanisms [2] - There is a significant market potential in the health industry, with a strong emphasis on identifying innovative drug projects with high clinical value and conversion potential [2][3] - The government encourages the cultivation of quality enterprises and provides policy support in areas such as talent and financing, while promoting international cooperation [2] Group 2: Research and Development Focus - The government stresses the importance of original innovation and tackling key core technologies, leveraging both government and market resources to foster innovation [3] - There is a call for the integration of artificial intelligence to enhance various stages of drug development, clinical trials, and production processes [3] - The government aims to modernize and industrialize traditional Chinese medicine by applying modern scientific theories and technologies [3]

Group 1 - The 2025 China International Service Trade Fair will be held from September 10 to 14 at the Shougang Park in Beijing, with a focus on health and wellness services as one of its nine key topics [1][4] - The annual theme is "Intelligent Leading the Future, Healthy Living," reflecting the impact of artificial intelligence technology on the healthcare industry [1] - The exhibition will feature two main experience zones: "Intelligent Therapy Cloud Matrix" and "Universal Health Service Matrix" [1] Group 2 - The event will showcase 15 stages of precise diagnosis and biomedicine AI research and development, highlighting benchmark applications and achievements in medical AI [2] - The traditional Chinese medicine sector will also present its achievements, with 48% of participating institutions being leading organizations in the field, marking a record high [2] - Notable institutions such as Tongrentang and the China Academy of Chinese Medical Sciences will demonstrate the modernization and international potential of traditional Chinese medicine [2] Group 3 - The "Capital International Medical Conference" will be held concurrently, focusing on topics such as technological innovation, pharmaceutical health industry development, and global health governance [3] - The conference will feature discussions led by renowned academicians and experts, showcasing innovative achievements in China's health sector and international cooperation [3] - Significant research reports, including the "BMJ China Hospital Clinical Research International Influence Report" and the "Digital Medical Blue Book," will be released [3]

Core Points - The forum titled "Integration of Industry, Academia, and Research on Classic Chinese Medicine Formulas" was held in Zhuhai, focusing on the internationalization of traditional Chinese medicine (TCM) [1][3] - The project "Pharmacological Verification and Formulation Optimization of Classic Formulas Huangqi Guizhi Wuwu Decoction and Taohong Siwu Decoction" was officially launched during the forum [1][21] - The event was co-hosted by the Macau University of Science and Technology and Beijing Tongrentang Group, highlighting the collaboration between academia and industry [1][3] Industry Development - The forum aimed to promote the industrialization and academic research of classic TCM formulas, facilitating cross-border exchanges [1][3] - Experts discussed the current state of the TCM industry and the development practices of classic formulas, providing strategies for modernization and internationalization [9][13] - The project received funding of over 12 million Macanese Patacas from the Macao SAR government, indicating strong governmental support for TCM development [21] Collaboration and Future Prospects - The collaboration between Macau University of Science and Technology and Tongrentang Group is seen as a significant step towards modernizing and internationalizing TCM [5][28] - The forum included discussions on the advantages of the Hong Kong-Macao TCM industry and the role of modern technology in TCM research [24][26] - Future efforts will focus on enhancing the international influence of the Tongrentang brand and expanding its market presence globally [7][28]

Core Viewpoint - Hubei University of Chinese Medicine has announced multiple government procurement intentions for laboratory instruments, with a total budget of 207 million yuan, focusing on advanced research equipment for traditional Chinese medicine [2][3]. Procurement Overview - The procurement includes 10 items of laboratory equipment, such as spectrometers and PCR instruments, with an expected procurement period from June to August 2025 [3]. - The total budget for the procurement is 207 million yuan [3]. Instrument Descriptions - **Spectrometer**: A precision instrument used to analyze the composition, structure, and physical-chemical properties of substances by measuring their interaction with electromagnetic waves or particles [4]. - **PCR Instrument**: Used for the in vitro amplification of specific DNA fragments, widely applied in fields such as medicine, biology, forensic science, and environmental monitoring [5]. Detailed Procurement List - The procurement list includes various instruments with specific functions, such as measuring specific elements' content and monitoring cellular physiological states [7][8]. - The budget for individual items varies, with significant allocations for advanced research equipment aimed at enhancing the capabilities of the university's research projects [8]. Institutional Background - Hubei University of Chinese Medicine, established in 1958, is the only higher education institution for traditional Chinese medicine in Hubei Province, recognized for its excellent educational standards [9]. - The university has a strong academic foundation with multiple doctoral and master's degree programs in traditional Chinese medicine and pharmacy [9]. Research and Development Achievements - The university has established several key laboratories and research centers focused on modernizing traditional Chinese medicine and has led numerous national research projects [10][11]. - Collaborations with enterprises have resulted in significant revenue generation, showcasing the practical impact of the university's research [11]. International Collaboration - The establishment of the China-Malaysia Traditional Chinese Medicine Center highlights the university's efforts to promote the internationalization of traditional Chinese medicine [12]. Talent Development - The university plans to recruit high-level research talents to enhance its research capabilities, indicating a commitment to strengthening its academic and research teams [14].

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. is leveraging its unique resources from the Changbai Mountain region to enhance its competitiveness in the traditional Chinese medicine industry, with a projected net profit growth of 130% to 140% year-on-year for the first half of the year [1] Group 1: Resource Utilization and Quality Control - The company has established the largest GAP-certified deer farm in Asia and a medicinal herb base in Changbai Mountain, ensuring the quality and stable supply of medicinal materials [2] - Jilin Aodong has built a standardized and large-scale medicinal herb planting base and employs a gene identification system for medicinal herbs, enhancing product innovation and quality control [2][3] - The company has developed a comprehensive database for northern medicinal herbs, addressing key challenges in seed breeding and standardized planting [3] Group 2: Innovation in Production and Technology - Jilin Aodong is focusing on modernizing traditional Chinese medicine through the development of granule formulations, which are seen as a key competitive advantage [4] - The company has invested 1 billion yuan in a granule formulation project, which will have an extraction capacity of 5,000 tons annually and is set to begin operations by the end of 2024 [4] - The extraction process has been fully automated, ensuring precise control over various parameters and enhancing product traceability and optimization [5] Group 3: Research and Development - The company has conducted over 5,000 studies on the processes and testing of granule formulations, successfully applying dynamic extraction and low-temperature concentration techniques [6] - Jilin Aodong has developed 525 varieties of granule formulations, including over 20 types of local medicinal materials from Jilin Province [6] Group 4: Talent Development and Financial Strategy - The company is building a diverse team of innovative talents and has established various national and local standards for the industry [7] - Jilin Aodong is enhancing its development model through a multi-wheel drive strategy that integrates medicine, finance, and health, with financial capital playing a crucial role [7] - The company aims to redefine the modernization path of the traditional Chinese medicine industry by integrating financial resources and digital technology to drive growth [7]

格隆汇8月5日丨粤万年青(301111.SZ)在互动平台表示，公司目前未生产或销售直接针对基孔肯雅热的药 品。基孔肯雅热是由基孔肯雅病毒引起，经伊蚊叮咬传播的病毒性传染病，其典型症状为发热。公司产 品中羚羊感冒胶囊功能主治清热解表。用于流行性感冒，伤风咳嗽，头晕发热，咽喉肿痛。除此之外， 感冒类产品还有扑感片、银菊清解片及银翘解毒合剂等，具体适用场景请以产品说明书或遵医嘱为准。 公司始终重视研发创新，目前公司在研产品及项目正在积极推进中，包括中药创新药研发和现有品种的 二次开发。未来，公司将继续加大研发投入，积极与汕头大学等高校探索产学研合作新模式，促进协同 创新，推动中医药现代化发展，增强公司的核心竞争力。 （原标题：粤万年青(301111.SZ)：目前未生产或销售直接针对基孔肯雅热的药品） ...